EPRX Eupraxia Pharmaceuticals posts wider than expected Q4 2025 loss on zero revenue shares dip nearly 1 percent Estrella Immunopharma ESLA Stock Dividend Yield Drifts Lower 20260420 SOLAI SLAI Stock Market Risk Exposure Volatility Increases 20260420 Is Niagen Bioscience NAGE stock losing bullish momentum Q4 2025 EPS Exceeds Expectations